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Abstract
The sublingual route has been proposed as a needle-free option to induce systemic and mucosal immune protection against
viral infections. In a translational study of systemic and mucosal humoral immune responses to sublingual or systemically
administered viral antigens, eighteen healthy female volunteers aged 19–31 years received three immunizations with a
quadravalent Human Papilloma Virus vaccine at 0, 4 and 16 weeks as sublingual drops (SL, n=12) or intramuscular injection
(IM, n=6). IM antigen delivery induced or boosted HPV-specific serum IgG and pseudovirus-neutralizing antibodies, HPV-
specific cervical and vaginal IgG, and elicited circulating IgG and IgA antibody secreting cells. SL antigens induced ,38-fold
lower serum and ,2-fold lower cervical/vaginal IgG than IM delivery, and induced or boosted serum virus neutralizing
antibody in only 3/12 subjects. Neither route reproducibly induced HPV-specific mucosal IgA. Alternative delivery systems and
adjuvants will be required to enhance and evaluate immune responses following sublingual immunization in humans.
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Introduction
The mucosal surface is the most common route of infection for a
wide range of viral diseases and therefore inducing both mucosal and
systemic immunity is a key objective of modern vaccines. The rich
infiltration into the sublingual mucosa of antigen-presenting dendritic
cells makes it an attractive route of immunization that avoids needles
and targets the mucosal immune system [1]. Virus-Like Particles
(VLP) comprising the Human Papilloma Virus (HPV) L1 major
capsid protein, as well as antigens from other viruses, delivered via the
sublingual route have been shown in mice to be highly immunogenic
and protective against subsequent viral challenge [2,3,4,5,6]. These
observations also support the idea of a ‘‘Common Mucosal Immune
System’’ and a link between the genital tract and the systemic immune
system [2,3,5,6]. However, while these studies have employed antigen
administration as simple sublingual liquid drops, there are character-
istics of murine models which need to be considered: the murine
sublingual surface is extremely rich in readily accessible dendritic cells
[1]; mice are routinely anaesthetized for sublingual immunization,
with possible anticholinergic effect on reducing saliva flow and antigen
clearance; cholera toxin and related mucosal adjuvants have been
employed to enhance responses, which may not be suitable for use in
humans [7]. Sublingual immunization with non-toxic cholera toxin B
subunit also induces and modulates local and disseminated responses,
but this antigen is almost unique in its mucosal immunostimulating
and adjuvant properties [8]. Sublingual delivery has been used for
many decades in humans in desensitizing regimes involving
prolonged, frequent delivery of high doses of allergens [9]. However,
it is only recently that this route has been considered for delivery of
prophylactic vaccine antigens, which will require far fewer doses at
lower dose levels [1,10]. We report here a preliminary human
translational study to determine the character, dissemination and
magnitude of systemic and mucosal immune responses to more
representative antigens from a vaccine already in widespread use
when administered sublingually or intramuscularly to healthy female
volunteers. These results are contrasted with data from broadly similar
murine studies in which HPV VLPs have been delivered sublingually
as simple drops and found to be highly effective in eliciting immune
response and protecting against genital HPV infection [3].
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
Ethical Approval was obtained from the UK National Research
Ethics Service, Wandsworth Research Ethics Committee reference
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participants after the nature and possible consequences of the
study was explained. Clarification of the legal status of the study
was obtained by submitting the protocol to the UK Medicines and
Healthcare products Regulation Agency (MHRA) which con-
firmed it as a ‘‘Characterization Study’’ and not a Clinical Trial of
an Investigational Medicinal Product (non-CTIMP/NIMP).
Although not a clinical trial, we registered this study protocol on
ClinicalTrials.gov (NCT00949572) prior to subject recruitment.
Objectives
We sought to characterize, and contrast, the nature and
dissemination of the immune response to sublingual or intramus-
cular deposition of meaningful viral vaccine antigens in humans,
and to compare this with published murine studies [2,3,4,5,6]. The
protocol defined no primary or secondary endpoints as this was
not a clinical trial. The goal was to describe the immune response
following immunization, and the study exploratory endpoint was
immune response measured as several immunologic factors and
assessed as change in each of these factors from pre to post
immunization. The following variables were assessed before and
after immunizations: (i) frequency of PBMCs secreting IgG or IgA
antibodies to HPV16 L1 VLPs and whole vaccine; (ii) concentra-
tion in the serum, cervical secretions and vaginal secretions of IgG
to HPV16, HPV6 and HPV18 L1 VLPs; (iii) concentration in the
cervical secretions and vaginal secretions of IgA to HPV16, HPV6
and HPV18 L1 VLPs; (iv) titer in the serum, cervical secretions
and vaginal secretions of neutralizing antibody to HPV16 or
Bovine Papillomavirus control.
Participants
The target recruitment defined by the protocol was 18 healthy
female volunteers (in two groups: SL n=12, IM, n=6) aged 25–
35. Subjects were all recruited at one site, St George’s - University
of London, London. As this was a hypothesis-generating study no
formal power calculation for sample size was performed. Inclusion
criteria included: provide written informed consent; in good health
determined by medical history, physical examination, hematology;
available for the duration of the study; if of childbearing potential,
must have a negative pregnancy test before each immunization;
have not donated blood in previous 3 months; eligible for free
medical treatment in the UK. Exclusion criteria included: already
received HPV vaccine; recent or concurrent participation in
another clinical research study; recent or planned use of any
investigational or non-registered product; pregnant or breast-
feeding; known or suspected ongoing cervico-vaginal disease,
malignancy or abnormality; positive results for Human Immuno-
deficiency Virus or Hepatitis B/C infection; abnormality in
hematology; acute or chronic pulmonary, cardiovascular, hepatic,
hematologic, renal, blood or neurological disorders, immune
dysfunction, autoimmune diseases, diabetes or malignancy; recent
immunosuppressive therapy; medications via vaginal route; tongue
or frenulum piercings or oral jewelry; recent receipt of blood
products or immunoglobulin.
Description of Procedures or Investigations undertaken
Immunization. We purchased the licensed quadravalent
Human Papilloma Virus (HPV) vaccine GardasilH (Sanofi
Pasteur), which contains L1-based virus-like particles (VLPs)
representing four HPV types: 20 mg each of HPV types 6, 18;
40 mg each of HPV types 16 and 11 per 0.5 mL dose. VLPs are
produced in yeast cells (Saccharomyces cerevisiae CANADE 3C-5
Strain 1895) by recombinant DNA technology and adsorbed on
amorphous aluminum hydroxyphosphate sulphate adjuvant (225
micrograms aluminum per dose). All subjects received three
immunizations with 0.5 mL (one standard dose) of vaccine at
weeks 0, 4 and 16 (table 1) which is a recommended schedule
within the flexibility of the usual 0, 1, 6 months dosing schedule for
parenteral immunization. IM immunizations were given into the
deltoid muscle. For SL immunization, subjects fasted (except
water) for 1 hour prior to challenge, then sat in an upright
position, rinsed the mouth with water and expectorated.
Absorbent pads (Molnlycke ‘Dry Tips’ small) were applied over
parotid duct openings bilaterally to absorb parotid saliva flow. The
tongue was raised and the sublingual area gently dried by brief
application of a cotton swab without inducing saliva flow from
submandibular and sublingual glands. The 0.5 mL contents of a
GardasilH syringe were dispensed drop-wise to the area behind the
sublingual fold bilaterally. The tongue was held in gentle
opposition to the floor of the mouth for 15 minutes without
swallowing, then the cotton pads removed and the subject allowed
to swallow. Subjects were fasted completely for 30 minutes under
observation and then requested to fast (including fluids) for a
further 60 minutes after leaving the clinical site.
Sample collection. Table 1 shows the schedule of
immunizations and sample collection. A blood sample was taken
before the first immunization, at the time of the first
immunization, and then on weeks 1, 4, 5, 8, 16, 17 and 20 after
first immunization. Cervical and vaginal wick samples were
collected at the time of the first immunization, and then on weeks
4, 16 and 20. Schedules were initiated to accommodate the
subjects’ menstrual cycles and a 62 day window period was
acceptable for all visits, except 1, 5 and 17 which had a 61 day
window. A protocol amendment was approved during the study to
collect cervical and vaginal samples at week 8 for 3/6 subjects in
IM group and 6/12 in SL group. To collect mucosal secretions a
Weck-Cel surgical spear was placed either in the cervical os or
against the vaginal wall for 2 minutes, then secretions eluted as
described previously [11]. Briefly, spearheads were snipped into
the top chamber of a Spin-X tube (Corning) containing 300 mL
sterile filtered extraction buffer (250 mM NaCl, 16 protease
inhibitor cocktail set 1 (Calbiochem) in phosphate buffered saline
(PBS)) and centrifuged at 4uC for 15 minutes at 13,000 g. A repeat
extraction was performed by adding additional extraction buffer to
the top chamber, and then 8 mL heat inactivated fetal calf serum
added to pooled secretions from each sample site, prior to
separation into 200 mL aliquots and freezing at 280uC before
batch analysis by ELISA as described below.
HPV L1 antigens used in ELISA and ELISPOT
assays. HPV11 L1 VLPs were not available and no responses
to HPV11 were measured. HPV 6 and 18 L1 VLPs were a kind
gift of Shantha Biotechnics Ltd, India. HPV16 L1 VLPs were
generated using the Bac-to-BacH Baculovirus Expression System
(Invitrogen) wherein the recombinant bacmid DNA contained an
HPV16 L1 gene with a 100% amino acid sequence identity to
Table 1. Schedule of immunizations and sample collection.
Week
014581 6 1 7 2 0
Immunization x x x
PBMCs sample x xxxxx x x
Serum sample x xxxxx x x
Cervical & vaginal secretions sample x x x x x
doi:10.1371/journal.pone.0033736.t001
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Recombinant HPV16-expressing baculovirus stocks were used to
infect Sf21 insect cells (Invitrogen) for 72 hours at 27uC before
lysis (IGEPALH CA-630; Sigma-Aldrich) at room temperature in
the presence of protease inhibitors (Complete; Roche). The cell
lysate was then subjected to iodixanol gradient fractionation and
gradient fractions were collected by bottom puncture and stored at
280uC. The L1 concentration and purity were visualized by SDS-
PAGE stained with Colloidal Blue (Invitrogen) and analyzed using
ImageJ software (U. S. National Institutes of Health, http://
imagej.nih.gov/ij). VLP formation was confirmed by electron
microscopic analysis of negatively staining particles (Phospho-
tungstic Acid; Sigma-Aldrich) adsorbed on copper grids coated
with formvar (Sigma-Aldrich) and carbon.
Frequency of circulating L1-specific IgG and IgA spon-
taneously antibody secreting cells (ASCs). The frequency of
L1-specific spontaneously antibody-secreting plasmablasts was
enumerated in PBMCs separated from heparinized whole blood
by Ficol gradient centrifugation in an ELISPOT assay as
described previously [12]. PVDF-backed 96 well plates (MAHA
S45, Millipore) were coated in advance, and divided into three
parts: coating buffer only in wells without any antigen as a
background and nonspecific reaction control; L1 HPV16 VLPs;
or GardasilH (as other L1 antigens were not available at this
time). The cell density of each sample was adjusted to 5610
5,
2.5610
5 and 1.25610
5/well using AIMV medium (Invitrogen,
UK) containing penicillin–streptomycin. Each cell concentration
was added as duplicate wells on the three antigens or uncoated
parts of the plate after blocking. A 2 mg/mL PHA positive
control was also added on each plate. After overnight incubation,
the specific antibody-secreting cells were recognized by the goat
anti-human IgG or IgA conjugated with alkaline phosphatase,
and counted and analyzed by the AID EliSpot Reader System.
The final results were standardized as positive cell number/
1610
5 PBMCs plated.
L1-specific IgG & IgA in serum, cervical & vaginal
secretion quantified by ELISA. The concentration of serum,
cervical or vaginal L1-specific IgG and IgA was measured by
indirect ELISA as described previously [11] using purified L1
HPV16, 6 and 18 VLPs in carbonate-bicarbonate buffer (0.05M
pH 9.6) coated individually on MaxiSorp plates (Nunc). One
standard curve made by a positive serum with known specific
antibody concentration, and positive and negative controls were
set-up on each plate, with two blank wells on each plate to monitor
background. Serum, cervical and vaginal samples were diluted 1/
200 or 1/4 with 0.05% PBS–T20, respectively, and any sample
with OD value above the upper limit of the standard curve was
further diluted and re-assayed. The specific IgG or IgA was
recognized by goat anti-human IgG or IgA conjugated with
peroxidase. The concentrations of specific antibodies were
measured by an Emax MAXLine Microplate reader at 650 nm
after the TMB liquid substrate developed. The raw OD data was
analyzed using SoftMaxH software.
Functional antibody in serum and cervical and vaginal
secretions measured by in vitro pseudovirus neutralization
assay. The HPV16 pseudovirus neutralization assay [13] was
carried out as previously described [14] and included Bovine
Papillomavirus (BPV) as a control for non-specific antibody
effects. As a control, the WHO International Standard for
HPV16 antibodies, IS16 (code: 05/134; 10 IU/mL; National
Institute for Biological Standards and Control, UK; [15])
demonstrated type-specific neutralization of HPV16 at levels
consistent with natural infection (median titer 138 [inter-quartile
range 115–148]; n=3).
Statistical methods
As this was not a clinical trial, no randomization was
performed and no safety data (adverse events) were solicited, no
primary or secondary endpoints were specified. Subjects were
allocated to one of two sequential cohorts: ‘‘IM’’ who received all
immunizations via the intramuscular route (n=6); and ‘‘SL’’ who
received all immunizations as sublingual drops (n=12). Subjects
were not randomized as we wished to develop and evaluate B cell
assays carried out on fresh blood samples by recruiting the first
subjects into the intramuscular delivery group (and for whom
measurable antibody secreting cells (ASCs) were likely to be seen).
As the immunization routes could not be blinded the study was
not blinded. There were no protocol deviations. As this
hypothesis-generating study was not powered to detect significant
differences between groups or between time points, no statistical
testing was performed and descriptive statistics only are
presented.
Results
Subjects enrolled
Eighteen female subjects aged 19–31 years (IM group mean
24.2, median 25; SL group mean 26.3, median 27.5) were enrolled
and completed the protocol. There were no protocol deviations
(figure 1).
Circulating Anti-L1 HPV16 B cell responses measured by
ELISPOT
HPV16 L1 VLPs and whole vaccine (VLP HPV 6, 11, 16 and
18) were used as a coating antigens. From previous studies using
oral, nasal or intramuscular immunization [12,16], a transient
increase in the frequency of cells spontaneously secreting ant-L1
IgG and IgA was expected, peaking around 7 days after each
immunization (on weeks 0, 4 and 16) and then falling back to
baseline, reflecting the generation and maintenance kinetics of
plasmablasts. An increase in IgG and IgA antibody secreting cell
(ASC) frequencies was seen after IM immunizations (figure 2), but
not after SL immunization.
Anti-L1 HPV6, HPV16 and HPV18 serum & cervico-vaginal
IgG & IgA responses measured by ELISA
The kinetics of the anti-HPV L1 VLP antibody response in
serum and in cervico-vaginal secretions was measured before and
at various time points after each immunization using an antigen-
specific antibody binding ELISA, with purified L1 HPV16, 6 and
18 VLPs as coating antigens. As expected, IM immunization
induced an increase in serum anti-HPV6, HPV18 and HPV16 L1
VLP IgG from baseline (figure 3). IM immunization also induced
an increase in cervical anti-HPV6 and HPV16 L1 VLP IgG, and
to a lesser extent in anti-HPV18 L1 VLP IgG. An increase in
vaginal anti-HPV6 and HPV16 L1 VLP IgG was seen, but not
anti-HPV18 L1 VLP IgG. SL immunization induced an increase
in anti-HPV16 L1 VLP IgG in serum, cervical secretions and
vaginal secretions, and a slight increase in cervical anti-HPV18 L1
VLP IgG. However, the serum anti-HPV16 L1 VLP IgG at week
20 after IM immunization was 219 mg/mL (SEM 657.3, a 38.9-
fold rise from week 0), compared with 5.73 mg/mL (62.9, 3.4-fold
rise) after SL immunization. In contrast, relative levels of specific
IgG in mucosal secretions were not as dissimilar as in serum: mean
45.5 ng/mL (610.8, 2.2-fold rise) in cervical secretions after SL
immunization, 76.7 ng/mL (619.6, 9.8-fold rise) after IM
immunization. Similarly, in vaginal secretions the values were
56.1 ng/mL (613.8, 3.2-fold rise) and 115.5 ng/mL (634.9, 10.9-
Sublingual Immune Responses
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responses in secretions were variable at all time points (figure 4).
Neutralization of HPV16 by serum and cervical and
vaginal secretions
The detection of antibodies capable of neutralizing HPV16
pseudoviruses was examined using serum and cervical and vaginal
samples taken at week 0 and 20 (4 weeks post last immunization)
for all subjects (table 1). Some intermediate time points were also
evaluated for selected subjects (data not shown). The control
Bovine Papillomavirus (BPV) was used as a control for non-specific
antibody reactivity. All subjects had undetectable virus neutrali-
zation titers in mucosal secretions at week 0 (table 2), but 2/6 and
1/12 subjects in the IM and SL groups, respectively, had
detectable serum virus neutralizing activity at week 0, which is
in line with the ,12% prevalence estimates for previous HPV16
infection expected in this population [17,18]. IM immunization
induced or boosted serum neutralizing antibodies in all subjects at
week 20, and very low level neutralizing titers also appeared in
mucosal secretions at week 20 after IM immunization in the 3/6
subjects with the highest serum neutralizing titers. Sublingual
immunization did not induce any neutralizing activity in mucosal
secretions. However, sublingual immunization did boost pre-
existing serum neutralizing activity in one subject (013) to a level
similar to that seen in subjects without pre-existing neutralizing
activity who received IM immunization and induced weak serum
neutralizing titers in two others (015, 023). This suggests that,
unlike IM immunization, while SL immunization may not be very
effective at priming the immune response it may be able to boost
pre-existing immunity.
Discussion
Parenteral immunization with vaccines containing HPV L1
VLPs and formulated using alum and/or TLR agonist adjuvants is
highly effective at inducing both serum and mucosal antibodies,
and conferring long-lasting protection against HPV infection by
the homologous or related HPV genotypes [19,20,21,22]. Several
murine models have shown that simple drops placed under the
tongue can induce functional antibody and T cell responses to
viruses such as Herpes simplex virus (HSV), influenza, Human
Immunodeficiency Virus (HIV) and HPV, and protection against
genital challenge with HSV and HPV [2,3,4,5,6]. The possibility
to develop a needle-free sublingual human vaccine, specifically
targeting the induction of mucosal immunity and applicable to a
wide range of genital viral infections is compelling [1]. However,
these murine models often incorporate features that are not
compatible with real-world human vaccine strategies, such as the
use of anti-cholinergic anesthetics that may block saliva flow, and
mucosal adjuvants based on cholera toxin-related proteins that are
unsafe in humans when given nasally [7]. Sublingual desensitiza-
tion regimes use frequent, prolonged high doses of allergens [9].
Non-toxic cholera toxin B subunit antigens induce disseminated
antibody responses after sublingual immunization, but this
molecule has intrinsic mucosal immunogenicity and adjuvanticity
not seen in the majority of protein antigens [8], and like allergens
may therefore not be representative of real word sublingual human
Figure 1. CONSORT diagram.
doi:10.1371/journal.pone.0033736.g001
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to characterize immune responses to the sublingual or parenteral
administration of a viral antigen that is already in widespread use
as a human vaccine [23], and therefore representative of the
human application of sublingual immunization. As this was the
first use of this vaccine sublingually in humans we followed a 0, 1,
4 month prime-boost schedule which is an acceptable schedule for
IM immunization using GardasilH.
We observed that sublingual immunization generally induced a
similar pattern of immune responses to intramuscular, but at much
lower magnitudes. An increase in serum anti-HPV16 L1 VLP IgG
was detected after both IM and SL immunization (figure 3).
However, the serum anti-HPV16 L1 VLP IgG at week 20 after IM
immunization was ,38 times higher than after SL immunization.
Similarly, while IM immunization was able to both prime or boost
serum virus neutralizing activity in all subjects, sublingual
immunization could only boost serum neutralizing activity in a
subject with pre-existing activity at week 0, and induce low levels
of serum neutralizing antibody in two other subjects with
undetectable neutralizing activity at day 0. This suggests that
with optimization, the sublingual route may have a role in
boosting pre-existing immunity induced by another route, and is
capable of inducing functional antibody.
One of the potential translational advantages proposed for
mucosal immunization is that it appears to specifically induce
mucosal immunity [10]. However, while IM immunization was
capable of inducing measurable virus neutralizing activity in
cervical and/or vaginal secretions in 3/6 subjects (concomitant
with high serum neutralizing titers suggesting transudation of
serum IgG), no mucosal virus neutralizing activity was induced by
SL immunization in any subject. Similarly, while IM immuniza-
tion induced increases in mucosal anti-HPV6 and HPV16 L1 VLP
IgG, sublingual immunization only induced an increase in
mucosal anti-HPV16 L1 VLP IgG. However, it is intriguing that
relative levels of specific IgG in mucosal secretions were not as
dissimilar as in serum with only ,1.7-fold higher levels in cervical
secretions after IM immunization compared with SL immuniza-
tion. Similarly, in vaginal secretions IM immunization gave ,2-
fold higher levels. This can be interpreted as SL immunization
preferentially favors mucosal over systemic responses, or that
neither route is very efficient at inducing mucosal immunity.
Mucosal IgA responses were infrequent, low level, transient and
extremely variable after either SL or IM immunization, despite
HPV-specific IgA ASC responses after IM immunization. The
kinetics of the ASC response to sublingual immunization is not
well defined in humans and it is possible that we missed the
Figure 2. Circulating antibody secreting cell responses. The Y axis values indicate the group median frequency of antibody secreting cells
(ASCs) per 10
5 PBMCs plated, secreting IgG (white bars) or IgA (hatched bars) against Gardasil vaccine or L1 HPV16. Panel A: subjects immunized
intramuscularly. Panel B: subjects immunized sublingually. Arrows indicate immunizations. Box: 25th to 75th percentiles, whiskers: 10 to 90
percentiles.
doi:10.1371/journal.pone.0033736.g002
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responses to the first IM immunization appeared higher than
subsequent immunizations, previous studies [16] have shown a
shift to a slightly earlier timing of the peak response to booster
immunizations (around day 5), which may explain the apparent
fall in frequency measured 7 days after the booster immunizations.
Due to the considerable volume of saliva produced despite
covering the parotid ducts, it is highly likely that some sublingually
administered VLPs would have been removed from the mucosal
surface within minutes of application. To be effective, extensive
optimization of sublingual delivery will be required to improve
penetration of the sublingual mucosa of humans, perhaps by
making use of mucoadhesives or other delivery systems designed to
resist salivary degradation [24]. In addition, the size of VLPs and
VLP-alum aggregates may have restricted access across the
mucosal barrier. Manipulation of the particle size may therefore
optimize responses. However, despite these caveats, some HPV-
specific immunity was generated de novo in 2/12 subjects whose day
0 serum neutralizing antibody titer was below the cut-off in our
assay, and boosted the day 0 titer in another subject. These
observations are encouraging for potential future vaccine strategies
based upon sublingual delivery. It is also possible that the bivalent
vaccine, CervarixH, which makes use of a TLR-4 agonist in the
vaccine formulation and has been shown to induce higher levels of
HPV-specific antibodies when administered parenterally, may
have induced significantly higher antibody levels [25], especially if
combined with mucosal delivery systems that enhance sublingual
contact times [24]. We allowed subjects to swallow retained saliva,
Figure 3. Serum, cervical and vaginal IgG responses. The Y axis values (note different scales) indicate group mean anti-L1 HPV6 (circles), HPV16
(triangles) and HPV18 (squares) IgG concentration in serum (panel A), cervical secretions (panel B) or vaginal secretions (panel C), for subjects
immunized intramuscularly (left, open symbols), or sublingually (right, closed symbols). Error bars SEM.
doi:10.1371/journal.pone.0033736.g003
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(squares) IgG concentration in cervical secretions (panel A), or vaginal secretions (panel B), for subjects immunized intramuscularly (left, open
symbols), or sublingually (right, closed symbols). Error bars SEM.
doi:10.1371/journal.pone.0033736.g004
Table 2. HPV16 pseudovirus neutralization by serum and genital antibodies.
HPV16 Neutralization Titer using in indicated sample
Cervix Vagina Serum
Immunization Route Subject ID Week 0 Week 20 Week 0 Week 20 Week 0 Week 20
Intramuscular 001 -
a - - - - 4,367
004 - - - 26 - 34,255
005 - - - - - 4,055
017 - - - - - 3,856
018 - 51 - 39 189 61,743
020 - 42 - 53 5,086 44,494
Sublingual 006 - - - - - -
007 - - - - - -
008 - - - - - -
009 - - - - - -
010 - - - - - -
011 - - - - - -
013 - - - - 213 2,249
014 - - - - - -
015 - - - - - 632
019 - - - - - -
021 - - - - - -
023 - - - - - 92
a‘-’, indicates reciprocal neutralization titers ,20. All samples tested negative for neutralizing antibodies against the control Bovine Papillomavirus, BPV.
doi:10.1371/journal.pone.0033736.t002
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to be induced in the small intestine. However, it is unlikely that
20–40 mg of VLPs would survive gastric acid, and indeed even the
uniquely immunogenic mucosal antigen and adjuvant cholera
toxin or its B subunit given at doses of 1–5 mg requires buffering
with bicarbonate solution to retain immunogenicity via the oral
route in humans [26,27].
In conclusion, this preliminary translational human study
indicates that, in marked contrast to murine studies, SL delivery
of a representative virus vaccine antigen formulated with alum is
only modestly immunogenic in humans. This route can, however,
induce low level serum and mucosal antibodies, and functional
serum neutralizing antibody. The observation that SL immuniza-
tion could boost pre-existing serum neutralizing activity also points
to the possible use of IM prime/SL boost schedules. For this
approach to be advanced, the next steps require significant
optimization of the SL delivery system for human use, and the
investigation of optimal SL-IM prime-boost schedules. Once this is
achieved the benefits of sublingual delivery on the character,
magnitude and dissemination of responses should be compared in
clinical trials.
Supporting Information
Protocol S1 Trial Protocol.
(PDF)
Checklist S1 CONSORT Checklist.
(DOC)
Acknowledgments
We are grateful for the kind gift of HPV 6, 11 and 18 VLPs from Shantha
Biotech, Hyderabad, India. We acknowledge the critical review of the
protocol and advice from Raphaelle El-Habib, Sanofi-Pasteur. We are
indebted to John T. Schiller and Christopher B. Buck (National Cancer
Institute, Bethesda, MD) for access to the pseudo virus clones used in this
study.
Author Contributions
Conceived and designed the experiments: SB DJML. Performed the
experiments: ZH SLB RG CO. Analyzed the data: ZH SLB SB DJML.
Contributed reagents/materials/analysis tools: SLB SB. Wrote the paper:
ZH SLB RG SB CO DJML.
References
1. Czerkinsky C, Cuburu N, Kweon MN, Anjuere F, Holmgren J (2011)
Sublingual vaccination. Hum Vaccin 7: 110–114.
2. Cho HJ, Kim JY, Lee Y, Kim JM, Kim YB, et al. (2010) Enhanced humoral and
cellular immune responses after sublingual immunization against human
papillomavirus 16 L1 protein with adjuvants. Vaccine 28: 2598–2606.
3. Cuburu N, Kweon MN, Hervouet C, Cha HR, Pang YY, et al. (2009)
Sublingual immunization with nonreplicating antigens induces antibody-
forming cells and cytotoxic T cells in the female genital tract mucosa and
protects against genital papillomavirus infection. J Immunol 183: 7851–7859.
4. Cuburu N, Kweon MN, Song JH, Hervouet C, Luci C, et al. (2007) Sublingual
immunization induces broad-based systemic and mucosal immune responses in
mice. Vaccine 25: 8598–8610.
5. Hervouet C, Luci C, Cuburu N, Cremel M, Bekri S, et al. (2010) Sublingual
immunization with an HIV subunit vaccine induces antibodies and cytotoxic T
cells in the mouse female genital tract. Vaccine 28: 5582–5590.
6. Song JH, Nguyen HH, Cuburu N, Horimoto T, Ko SY, et al. (2008) Sublingual
vaccination with influenza virus protects mice against lethal viral infection. Proc
Natl Acad Sci U S A 105: 1644–1649.
7. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, et al. (2009) Transient
facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically
detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4: e6999.
8. Holmgren J, Adamsson J, Anjuere F, Clemens J, Czerkinsky C, et al. (2005)
Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based
on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 97:
181–188.
9. Frati F, Moingeon P, Marcucci F, Puccinelli P, Sensi L, et al. (2007) Mucosal
immunization application to allergic disease: sublingual immunotherapy. Allergy
Asthma Proc 28: 35–39.
10. Czerkinsky C, Holmgren J (2010) Mucosal Delivery Routes for Optimal
Immunization: Targeting Immunity to the Right Tissues. Curr Top Microbiol
Immunol.
11. Lewis DJ, Fraser CA, Mahmoud AN, Wiggins RC, Woodrow M, et al. (2011)
Phase I Randomised Clinical Trial of an HIV-1(CN54), Clade C, Trimeric
Envelope Vaccine Candidate Delivered Vaginally. PLoS One 6: e25165.
12. Mills KH, Cosgrove C, McNeela EA, Sexton A, Giemza R, et al. (2003)
Protective levels of diphtheria-neutralizing antibody induced in healthy
volunteers by unilateral priming-boosting intranasal immunization associated
with restricted ipsilateral mucosal secretory immunoglobulin a. Infect Immun
71: 726–732.
13. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, et al. (2004)
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based
papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:
205–216.
14. Draper E, Bissett SL, Howell-Jones R, Edwards D, Munslow G, et al. (2011)
Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7
and A9 species groups by bivalent HPV vaccine sera. Vaccine 29: 8585–8590.
15. Ferguson M, Wilkinson DE, Heath A, Matejtschuk P (2011) The first
international standard for antibodies to HPV 16. Vaccine 29: 6520–6526.
16. Lewis DJ, Novotny P, Dougan G, Griffin GE (1991) The early cellular and
humoral immune response to primary and booster oral immunization with
cholera toxin B subunit. Eur J Immunol 21: 2087–2094.
17. Desai S, Chapman R, Jit M, Nichols T, Borrow R, et al. (2011) Prevalence of
human papillomavirus antibodies in males and females in England. Sex Transm
Dis 38: 622–629.
18. Jit M, Vyse A, Borrow R, Pebody R, Soldan K, et al. (2007) Prevalence of
human papillomavirus antibodies in young female subjects in England.
Br J Cancer 97: 989–991.
19. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al.
(2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16,
and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic
nonvaccine HPV types in generally HPV-naive women aged 16–26 years.
J Infect Dis 199: 926–935.
20. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al.
(2009) A pooled analysis of continued prophylactic efficacy of quadrivalent
human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical
and external genital lesions. Cancer Prev Res (Phila) 2: 868–878.
21. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, et al. (2009) Efficacy
of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against
cervical infection and precancer caused by oncogenic HPV types (PATRICIA):
final analysis of a double-blind, randomised study in young women. Lancet 374:
301–314.
22. Schiller JT, Lowy DR (2010) Vaccines to prevent infections by oncoviruses.
Annu Rev Microbiol 64: 23–41.
23. Frazer I (2007) Correlating immunity with protection for HPV infection.
International Journal of Infectious Diseases 11: S10–S16.
24. Moingeon P, Lombardi V, Saint-Lu N, Tourdot S, Bodo V, et al. (2011)
Adjuvants and vector systems for allergy vaccines. Immunol Allergy Clin North
Am 31: 407–419, xii.
25. Pomfret TC, Gagnon JM, Jr., Gilchrist AT (2011) Quadrivalent human
papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeco-
nomics. J Clin Pharm Ther 36: 1–9.
26. Clemens JD, Jertborn M, Sack D, Stanton B, Holmgren J, et al. (1986) Effect of
neutralization of gastric acid on immune responses to an oral B subunit, killed
whole-cell cholera vaccine. J Infect Dis 154: 175–178.
27. Levine MM, Hughes TP, Young CR, O’Donnell S, Craig JP, et al. (1978)
Antigenicity of purified glutaraldehyde-treated cholera toxoid administered
orally. Infect Immun 21: 158–162.
Sublingual Immune Responses
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33736